Imricor Medical Systems Names US Academic Health System as Third Site for Heart Procedure Trial

MT Newswires Live

Yesterday

Imricor Medical Systems (ASX:IMR) said Virginia Commonwealth University Health in the US will serve as the third site in the company's Vision-MR Ablation Catheter 2.0 for Treatment of Type I Atrial Flutter (VISABL-AFL) clinical trial, according to a Wednesday filing with the Australian bourse.

The trial investigates the safety and efficacy of radiofrequency ablation of ventricular tachycardia performed with the company's product Vision-MR Ablation Catheter 2.0, the company said in an August 2023 statement.

The company expects to start final budgeting, installation, and training at the site in February and procedures in March, the filing said.

Shares of the company fell 1% in recent Wednesday trade.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/2605883128"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2605883128\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2605883128?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-21 08:12","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2605883128","market":"sh","top_or_hot":-1,"title":"Imricor Medical Systems Names US Academic Health System as Third Site for Heart Procedure Trial","media":"MT Newswires Live","content":"<html><body><p> Imricor Medical Systems (ASX:IMR) said Virginia Commonwealth University <a href=\"https://laohu8.com/S/HIT\">Health in</a> the US will serve as the third site in the company's Vision-MR Ablation Catheter 2.0 for Treatment of Type I Atrial Flutter (VISABL-AFL) clinical trial, according to a Wednesday filing with the Australian bourse.</p><p>The trial investigates the safety and efficacy of radiofrequency ablation of ventricular tachycardia performed with the company's product Vision-MR Ablation Catheter 2.0, the company said in an August 2023 statement.</p><p>The company expects to start final budgeting, installation, and training at the site in February and procedures in March, the filing said.</p><p>Shares of the company fell 1% in recent Wednesday trade.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Imricor Medical Systems Names US Academic Health System as Third Site for Heart Procedure Trial</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nImricor Medical Systems Names US Academic Health System as Third Site for Heart Procedure Trial\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-01-21 08:12</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Imricor Medical Systems (ASX:IMR) said Virginia Commonwealth University <a href=\"https://laohu8.com/S/HIT\">Health in</a> the US will serve as the third site in the company's Vision-MR Ablation Catheter 2.0 for Treatment of Type I Atrial Flutter (VISABL-AFL) clinical trial, according to a Wednesday filing with the Australian bourse.</p><p>The trial investigates the safety and efficacy of radiofrequency ablation of ventricular tachycardia performed with the company's product Vision-MR Ablation Catheter 2.0, the company said in an August 2023 statement.</p><p>The company expects to start final budgeting, installation, and training at the site in February and procedures in March, the filing said.</p><p>Shares of the company fell 1% in recent Wednesday trade.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK7508","symbol_name":"医药生物股","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2605883128","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2605883128","pubTimestamp":1768954351,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Imricor Medical Systems  said Virginia Commonwealth University Health in the US will serve as the third site in the company's Vision-MR Ablation Catheter 2.0 for Treatment of Type I Atrial Flutter  clinical trial, according to a Wednesday filing with the Australian bourse.The trial investigates the safety and efficacy of radiofrequency ablation of ventricular tachycardia performed with the company's product Vision-MR Ablation Catheter 2.0, the company said in an August 2023 statement.The company expects to start final budgeting, installation, and training at the site in February and procedures in March, the filing said.Shares of the company fell 1% in recent Wednesday trade.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK7508":"医药生物股","BK7503":"科技股","IMR.AU":"IMRICOR MEDICAL SYSTEMS-CDI","BK7007":"医疗保健设备"},"translate_title":"Imricor Medical Systems将美国学术卫生系统指定为心脏手术试验的第三个地点","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IMR.AU":1},"content_text":"Imricor Medical Systems (ASX:IMR) said Virginia Commonwealth University Health in the US will serve as the third site in the company's Vision-MR Ablation Catheter 2.0 for Treatment of Type I Atrial Flutter (VISABL-AFL) clinical trial, according to a Wednesday filing with the Australian bourse.The trial investigates the safety and efficacy of radiofrequency ablation of ventricular tachycardia performed with the company's product Vision-MR Ablation Catheter 2.0, the company said in an August 2023 statement.The company expects to start final budgeting, installation, and training at the site in February and procedures in March, the filing said.Shares of the company fell 1% in recent Wednesday trade.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}